Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29225364 | 0.86 | CNR1 (0.42) | KDM4EALDH1A1CNR2HPGDNPC1 | |
| SCHEMBL9807560 | 0.84 | CNR1 (0.47) | KDM4EALDH1A1CNR2HPGDNPC1 | |
| SCHEMBL22367245 | 0.84 | CNR2 (0.40) | KDM4EALDH1A1CNR2NPC1MAPT | |
| SCHEMBL2040857 | 0.84 | KDM4E (0.41) | KDM4EALDH1A1HPGDHSD17B10NPC1 | |
| SCHEMBL24434780 | 0.83 | KDM4E (0.42) | KDM4EALDH1A1CNR2HPGDNPC1 | |
| SCHEMBL16467932 | 0.83 | CNR2 (0.41) | KDM4EALDH1A1CNR2NPC1MAPT | |
| SCHEMBL2451961 | 0.83 | CNR1 (0.46) | KDM4EALDH1A1CNR2TLR8 | |
| SCHEMBL1422343 | 0.83 | CNR2 (0.47) | KDM4EALDH1A1CNR2NPC1MAPT | |
| SCHEMBL11463498 | 0.82 | NPC1 (0.46) | KDM4EALDH1A1CNR2HPGDHSD17B10 | |
| SCHEMBL18322299 | 0.81 | KDM4E (0.41) | KDM4EALDH1A1CNR2HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11401270-B2 | Alcoxyamino derivatives for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2022-08-02 | — | — | US | disclosed |
| EP-3700890-B1 | ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS SA (ES) | 2021-11-17 | — | — | EP | disclosed |
| US-20200299297-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-09-24 | — | — | US | disclosed |
| EP-3700890-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299297-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | CACNA1B, CACNB2, CACNA1G | KDM4E 2864/4885ALDH1A1 771/4885CNR2 185/4885 |
| US-11401270-B2 | Alcoxyamino derivatives for treating pain and pain related conditions | CACNA1B, CACNA1G, CACNA2D2 | KDM4E 2858/4885ALDH1A1 713/4885CNR2 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.